Low T that isn't really low T — the functional hypogonadism story

This is the low-T-with-normal-labs problem, and it has several layers.

The first layer is the reference range itself. The 264–916 ng/dL range — or whatever variant your lab uses — was not established by studying what testosterone level produces optimal health and function in men across the lifespan. It was established by measuring testosterone in a population sample, calculating the middle 95 percent of values, and calling that the range. The population used for those historical ranges was not, in most cases, composed entirely of healthy young men. It included older men, men with subclinical illness, men with obesity, men with poor sleep. The bottom of the range reflects, in part, what testosterone looks like in men who are unwell. A 35-year-old man with symptoms of hypogonadism and a total testosterone of 380 is technically "in range" by this standard. Whether 380 is optimal for that man — whether it represents where he should be — is a different question that the lab range cannot answer.

The second layer is free testosterone. Total testosterone measures everything in the blood: testosterone tightly bound to SHBG, loosely bound to albumin, and free. Only the free and albumin-bound portions are bioavailable — available to enter cells and bind androgen receptors. SHBG rises with age, with certain medications, with hypothyroidism, with liver disease, and with caloric restriction. When SHBG is high, a larger proportion of total testosterone is bound and physiologically unavailable. A man with a total testosterone of 450 and an SHBG of 70 nmol/L may have free testosterone in the functionally deficient range even though his total looks acceptable. Free testosterone — either directly assayed or calculated from total T, SHBG, and albumin — frequently tells the story that total T obscures. And yet free testosterone is still routinely omitted from standard workups, and when providers do look at it, the reference ranges suffer from the same population-derivation problem as total testosterone ranges.

This is not a fringe position. Several professional societies and researchers in the men's health space have argued that the conventional diagnostic threshold for hypogonadism is set too low to capture all men who are symptomatic and would benefit from evaluation and intervention. The debate is unresolved. But for the man sitting across the desk from a doctor who is telling him his labs are fine while his lived experience says otherwise, understanding that the reference range is a statistical artifact — not a biological truth — is the beginning of a more useful conversation.

The third layer is the distinction between primary and secondary hypogonadism — a distinction that shapes what treatment or intervention makes sense. In primary hypogonadism, the problem is at the testicular level. The testes are not producing adequate testosterone despite receiving appropriate stimulation from the pituitary. LH and FSH are elevated because the brain is working harder to drive a failing system. Primary hypogonadism — caused by genetic conditions, prior testicular trauma, chemotherapy, or autoimmune damage — is less reversible and more likely to require replacement therapy.

Secondary hypogonadism is a different picture. Here, the testes are capable of producing testosterone, but the upstream signaling is inadequate. LH and FSH are low or inappropriately normal despite low testosterone — the brain is not driving hard enough. And secondary hypogonadism is frequently functional, meaning it is caused by an identifiable and often reversible factor, not by structural damage. The most common drivers of functional secondary hypogonadism in middle-aged men are obesity and the aromatase-excess it produces, obstructive sleep apnea, chronic opioid use, and chronic psychological stress. Elevated estradiol — from excess aromatization in adipose tissue — feeds back to the hypothalamus and pituitary to suppress GnRH and LH, respectively, driving testosterone down from the top of the cascade rather than from the bottom. This is not a damaged HPG axis. This is a suppressed one, and the suppression is, in principle, reversible.

This is the critical distinction that the "your labs are normal" response misses. If a man with a BMI of 32, sleep apnea, and testosterone of 380 is given TRT, he may feel better — but he has not addressed the functional suppression that was driving his low T. He has added fuel to a car whose engine was running on the wrong mixture. The functional suppression continues. The aromatase excess continues. His estradiol may rise further on TRT if not managed carefully. The underlying cause has been bypassed, not resolved.

The upstream interventions matter, and they produce measurable hormonal effects. Weight loss — specifically visceral fat reduction — lowers aromatase activity, reduces estradiol, and allows GnRH and LH to increase, which raises testosterone. A 10 percent reduction in body weight has been shown to produce meaningful increases in testosterone in men with obesity-related suppression. Treatment of sleep apnea improves the LH pulsatility that suppressed sleep was blunting. Tapering opioids, when medically appropriate, restores GnRH tone that opioids directly suppress. These are not minor interventions. They are the primary interventions, and for men with functional secondary hypogonadism, they may restore hormonal status to a level that resolves symptoms without pharmacological replacement.

Where pharmacological tools enter is in the situation where lifestyle and upstream correction have been addressed, or where the functional suppression is severe enough that symptom burden is high while those interventions are in progress, or where a man is making an informed decision about optimization rather than replacement. Enclomiphene and clomiphene are selective estrogen receptor modulators — non-peptide compounds that block estrogen feedback at the pituitary, allowing LH to rise and driving endogenous testosterone production upward. They are a reasonable option for men with secondary hypogonadism who want to preserve testicular function and endogenous production. Kisspeptin-10, a hypothalamic neuropeptide upstream of GnRH, has been researched for its role in stimulating the HPG axis from the top — a more physiological approach to reactivating a suppressed system. HCG, acting as an LH analog, can directly stimulate Leydig cell testosterone production and is commonly used in men's health clinics either alongside TRT or as a standalone approach. All of these operate through different points in the same axis, and the appropriate choice depends on the clinical picture: where in the axis the suppression is occurring, what the underlying driver is, and what the man's goals are regarding fertility.

TRT itself — testosterone replacement therapy — is FDA-approved for clinical hypogonadism and has a well-established evidence base in that context. For men in the "low-normal" territory, the decision to use TRT is more nuanced, involves a genuine conversation about benefits and risks, and should follow rather than precede a serious investigation into functional causes. The risks of TRT — suppression of endogenous production and spermatogenesis, erythrocytosis, cardiovascular considerations that are still being studied — are real and deserve honest discussion with a prescribing provider.

The most useful thing a man in this situation can do is arrive at a clinical appointment not just with a total testosterone number, but with free testosterone, SHBG, LH, FSH, estradiol, prolactin, and morning timing on all of it. That panel tells a story. It distinguishes primary from secondary, functional from structural, reversible from not. It gives the provider and the patient a map rather than a single data point. The "normal labs" conversation usually happens because only total testosterone was measured and compared against a statistical range. The fuller picture is where the clinical truth lives. Getting there requires a provider who thinks systematically about HPG axis function — and a patient who knows to ask for the full panel, to understand what the numbers mean, and to push past the reassurance that a single number in a wide range is a complete answer.

The fatigue, the flat mood, the diminished libido, the body composition that won't respond — these are real symptoms. They deserve a real investigation. Normal does not mean optimal, and optimal is a clinical question, not a lab reference question.